[Adoptive immunotherapy of malignancies].

The results of the studies show that mononuclear leukocytes isolated from human peripheral blood, malignant effusions, and surgically removed spleen can be generated into lymphokine-activated killers (LAK) characterized by high anti-tumor activity. LAKs may be used foradoptive immunotherapy of malignant effusions and the prevention of tumor recurrence in oncological patients after radical surgery.

[Surgical treatment of stage III-IV ovarian cancer]. / Khirurgicheskoe lechenie raka iaichnikov III-IV stadii.

A residual tumor after primary cytoreductive surgery is one of the most important factors of survival of patient with advanced ovarian cancer. Maximal cytoreduction can be achieved by different ways. We studied results of extended, combined and standard operations on patients treated in the Russian Cancer Research Center of the Russian Academy of Medical Sciences in 1989-1999. It was found that only optimal cytoreduction resulted in the absence of recurrences and better overall survival of the patients independent of the operation type (extended, combined or standard).

[Comparative study of cytosolic proteins in normal and neoplastic ovaries by polyacrylamide electrophoresis]. / Sravnitel'noe issledovanie belkov tsitozolia normal'nykh i opukholevykh tkanei iaichnikov metodom élektroforeza v poliakrilamidnom gele.

The report discusses the data on cytoplasmic protein occurrence in ovarian tissue (106) obtained by polyacrylamide gel electrophoresis. They were identified in normal ovarian tissue (15), benign tumor (16), primary malignant tumor (55) and tumor tissue after chemotherapy (20). A band was detected in the area of molecular 36 cD in malignant epithelial tumor tissue which was not seen in either normal, benign tumor tissue or after successful chemotherapy.

[Surgical treatment of patients with borderline serous tumors of the ovary]. / Khirurgicheskoe lechenie bol'nykh seroznymi pogranichnymi opukholiami iaichnikov.

The paper deals with the data on treatment of 63 patients with serous borderline tumors of the ovary (SBTO). Mean age was 40.2 years. The study included 30 patients (47.6%) with stage IA tumor, 15 (23.8%)--IB, 4 (6.3%)--II and 14 (22.2%)--stage III. Relapse frequency was 14.3%, irrespective of stage and method of therapy. Surgery was given to 18 patients (28.6%), combined therapy--by 45 (71.4%). Recurrent tumor was recorded after surgery in 2 (3.2%) and in 7 (14.8%) after combined therapy. Generally, surgery is the main treatment received by patients with SBTO. Adjuvant chemotherapy was not followed by decrease in relapse rates.